Meet Anne Tsao, M.D.
Anne S. Tsao, MD
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
VP, Academic Affairs, Division of Academic Affairs, Sr VP Office, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Thoracic Section Chief, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Thoracic Chemo-Radiation Program, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center THNMO, Houston, TX
Director, Mesothelioma Program, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center THNMO, Houston, TX
Clinical Medical Director, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2021 | Massachusetts Institute of Technology (MIT) Sloan School of Management, Cambridge, MA, USA, MBA, Business Administration |
| 1998 | University of Chicago, Pritzker School of Medicine, Chicago, IL, USA, MD, Medicine |
| 1994 | Massachusetts Institute of Technology, Cambridge, MA, USA, BS, Molecular Biology |
Postgraduate Training
| 2001-2004 | Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1998-2001 | Internal Medicine, Internal Medicine, Indiana University Department of Internal Medicine, Indianapolis, IN |
Board Certifications
| 2014 | American Board of Internal Medicine - Board Certified for Medical Oncology Specialty |
| 2004 | American Board of Internal Medicine - Board Certified for Medical Oncology Specialty |
Experience & Service
Academic Appointments
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2016
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2010
Administrative Appointments/Responsibilities
Committee Chair, MD Anderson Cancer Center Conflict of Interest Committee, Houston, TX, 2018 - 2021
Committee Chair, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center Thoracic Multi-disciplinary Tumor Board, Houston, TX, 2018 - 2021
Committee Chair, The University of Texas MD Anderson Cancer Center Scientific Review Committee, Houston, TX, 2010 - 2021
Institutional Committee Activities
Member, MDACC IND Task Force, 2017 - 2018
Member, The University of Texas MD Anderson Cancer Center Conflict of Interest Committee, 2015 - 2021
Member, The University of Texas MD Anderson Cancer Center Calabresi/K12 Internal Advisory Board, 2014 - 2019
Member, The University of Texas MD Anderson Cancer Center Electronic Protocol Accrual Auditing Committee (ePAAC), 2013 - 2019
Member, The University of Texas MD Anderson Cancer Center Clinical Research Billing Compliance Subcommittee (CRBCS), 2012 - 2021
Member, The University of Texas MD Anderson Cancer Center Ethics and Compliance in Oncology Research Conference, 2011 - 2013
Member, The University of Texas MD Anderson Cancer Center ACS-IRG Study Section Committee, 2011 - 2013
Chair/Co-Chair, The University of Texas MD Anderson Cancer Center Clinical Research Committee (CRC), 2010 - 2018
Associate Member, The University of Texas MD Anderson Cancer Center Institutional Review Board, 2010 - 2013
Member, The University of Texas MD Anderson Cancer Center Pharmacy and Therapeutics Committee, 2009 - 2011
Member, The University of Texas MD Anderson Cancer Center Clinical Research Committee (CRC), 2008 - 2021
Member, The University of Texas MD Anderson Cancer Center Internal Advisory Committee for the Integrative Medicine Program, 2003 - 2005
Honors & Awards
| 2021 | 2021 Best & Brightest EMBA, Poets & Quants for Executives |
| 2021 | President's Recognition of Faculty Excellence - Excellence in Clinical Quality Improvement, MD Anderson Cancer Center |
| 2020 | Virtual Methods Workshop, AACR |
| 2020 | 2020 Winner MIT Organizational Lab Competition, MIT |
| 2020 | AACR Team Science Award - TCGA Project Team, AACR |
| 2018 | Bristol Myers Squibb Women's History Month Grand Rounds, Bristol Myers Squibb Network of Women |
| 2017 | ASCO Advocacy Champion 2017, ASCO |
| 2016 | ASCO Advocacy Champion 2016, ASCO |
| 2013 | Fleming Fellowship for Mesothelioma Cancer Research, Fleming Foundation |
| 2013 | Ronald E. & Rebecca M. Kennedy Endowment for Lung Cancer, Ronald E. & Rebecca M. Kennedy Endowment |
| 2013 | Aileen M. Dillon & Lee M. Bourg Mesothelioma Fund, Aileen M. Dillon & Lee M. Bourg Mesothelioma Fund |
| 2013 | HOPE Foundation Mesothelioma Research, SWOG |
| 2012 | ASCO Leadership Development Program, ASCO |
| 2007 | ASCO Career Development Award, ASCO |
| 2005 | Head and Neck SPORE Career Development Award, Head and Neck SPORE |
| 2004 | American Society of Clinical Oncology, Merit Award, ASCO |
| 2003 | American Society of Clinical Oncology, Young Investigator Award, ASCO |
| 2003 | National Institute of Health Clinical Research Loan Repayment Award, National Institute of Health |
| 2003 | Glaxo-Smith-Kline National Fellowship Competition, Glaxo-Smith-Kline |
| 2003 | University of Texas MD Anderson Cancer Center Division of Cancer Medicine Excellence in Research Award, M. D. Anderson Cancer Center |
| 2002 | Workshop Methods in Clinical Cancer Research, AACR-ASCO |
| 2001 | Finalist Award Winner Indiana University Resident/Fellow Research Competition, Indiana University |
| 1999 | National Institute of Health Summer Research Award, National Institute of Health |
Selected Publications
Peer-Reviewed Articles
- Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol. e-Pub 2022. PMID: 36087590.
- Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 33(5):488-499, 2022. e-Pub 2022. PMID: 35124183.
- Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):702-709, 2022. e-Pub 2021. PMID: 34550757.
- Riely GJ, Ahn MJ, Felip E, Ramalingam SS, Smit EF, Tsao AS, Alcasid A, Usari T, Wissel PS, Wilner KD, Johnson BE. Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. Future Oncol 18(7):781-791, 2022. e-Pub 2021. PMID: 34918546.
- Tsao AS, Pass HI, Rimner A, Mansfield AS. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol 40(6):JCO2101567, 2022. e-Pub 2022. PMID: 34985934.
- Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao, AS , Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov 11(7):1688-1699, 2021. e-Pub 2021. PMID: 33632775.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao, AS , Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. e-Pub 2021. PMID: 33603241.
- Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397(10272):375-386, 2021. e-Pub 2021. PMID: 33485464.
- Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34957368.
- Milbury K, Li Y, Durrani S, Liao Z, Tsao AS, Carmack C, Cohen L, Bruera E. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and their Spouses: Results of a 3-Arm Pilot Randomized Controlled Trial. Oncologist 25(11):e1794-e1802, 2020. e-Pub 2020. PMID: 32621630.
- Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist 25(10):1457-1463, 2020. e-Pub 2020. PMID: 32608142.
- Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res 26(20):5477-5486, 2020. e-Pub 2020. PMID: 32816946.
- Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
- Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
- Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, Swisher S. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book 40:1-12, 2020. PMID: 32298162.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2019. PMID: 31778797.
- Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez DR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo BW, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer 1(2):176-183, 2020. e-Pub 2020. PMID: 34505064.
- Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol 37(28):2537-2547, 2019. e-Pub 2019. PMID: 31386610.
- Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol 14(10):1718-1731, 2019. e-Pub 2019. PMID: 31470129.
- Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69(5):402-429, 2019. e-Pub 2019. PMID: 31283845.
- Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 7(7):569-580, 2019. e-Pub 2019. PMID: 31103412.
- Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
- Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
- Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 13(11):1655-1667, 2018. e-Pub 2018. PMID: 30266660.
- Tsao AS, Gladish GW, Gill RR. Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. J Thorac Oncol 13(7):871-873, 2018. PMID: 29935841.
- Gary Lyman, Edward Balaban, Michael Diaz, Andrea Ferris, Tsao AS, Emile Voest, Robin Zon, Michael Francisco, Sybil Green, Shimere Sherwood, R. Donald Harvey*, Richard L. Schilsky. American Society of Clinical Oncology Position Statement: Biosimilars in Oncology. Journal of Clinical Oncology 20(36):1260-1265, 2018. PMID: 29443651.
- Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33(2):244-258.e10, 2018. PMID: 29438696.
- Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res 23(24):7483-7489, 2017. e-Pub 2017. PMID: 28972039.
- Tsao AS, Ignacio Wistuba, Dianren Xia, Lauren Byers, Lixia Diao, Jing Wang, Vassiliki Papadimitrakopoulou, Ximing Tang, Wei Lu, Humam Kadara, Dimitry Grigoryev, Myvizhi Esai Selvan, Zeynep H. Gümüş, Zhi Tan, Shuxing Zhang, Monique Nilsson, John V. Heymach. Germline and Somatic Smoothened Mutations in Non–Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. Journal of Clinical Oncology Precision Oncology, 2017. e-Pub 2017.
- David B. Nelson, David C. Rice, Jiangong Niu, Scott Atay, Ara A. Vaporciyan, Mara Antonoff,Wayne L. Hofstetter, Garrett L.Walsh, Stephen G. Swisher, Jack A. Roth,Tsao AS, Daniel Gomez, Sharon H. Giordano, RezaMehran, Boris Sepesi. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. Journal of Clinical Oncology 35(29):3354-3362, 2017. e-Pub 2017. PMID: 28817374.
- Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18(9):1261-1273, 2017. e-Pub 2017. PMID: 28729154.
- Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
- Papadimitrakopoulou V, Lee JJ, Wistuba II,Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE 2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with advanced Non-Small Cell Lung Cancer. J Clin Oncol. e-Pub 2016. PMID: 27480147.
- Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol 34(23):2761-8, 2016. e-Pub 2016. PMID: 27325859.
- Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16(4):447-56, 2015. e-Pub 2015. PMID: 25800891.
- Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 2012. PMID: 23059780.
- Tsao AS, Roth JA, Herbst RS. Future directions in multimodality therapy for III A NSCLC: Intergroup Trial 0139. Nat Rev Clin Oncol 7(1):10-12, 2010. PMID: 20029443.
- Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant Pleural Mesothelioma. J Clin Oncol 27(12):2081-90, 2009. e-Pub 2009. PMID: 19255316.
- Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-1970, 2007. PMID: 17620427.
- Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinical-Pathological Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. J Thorac Oncol 1(3):231-239, 2006. PMID: 17409862.
- Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg 15(4):405-20, 2003. PMID: 14710383.
- Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM. Increased phospho-AKT (Ser473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12(7):660-664, 2003. PMID: 12869408.
- Zauderer MG, Tsao, AS , Fennell DA, Bretscher MT, Davies J, Wong W, Pattipaka T, Peake MD. Treatment and Referral Patterns in Malignant Pleural Mesothelioma Patients in the USA. Journal of Thoracic Oncology.
Manuals, Teaching Aids, Other Teaching Publications
- Pass H, Tsao A, Rosenzweig K.. UptoDate: Initial Management of malignant pleural mesothelioma. UptoDate, 2022.
- Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2022.
Abstracts
- Tsao, AS , Zihe Song, Alan Loh Ho, Janice M. Mehnert, Edith P. Mitchell, John Joseph Wright, Naoko Takebe, Robert James Gray, Victoria Wang, Lisa McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O’Dwyer, Alice P. Chen, Keith Flaherty. Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). e-Pub 2022.
- Garland LL, Ou SH, Moon J, Mack PC, Testa J, Tsao AS, Wozniak AJ, Gandara DR. SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). e-Pub 2012.
Grant & Contract Support
| Title: | ASCO Career Development Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Head and Neck SPORE Career Development Award |
| Funding Source: | Head and Spore |
| Role: | Principal Investigator |
| Title: | PROSPECT. Profiling of Resistance Patterson and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification (Project 4) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Project Leader |
| Title: | National Institute of Health K12 Clinician Investigator Award |
| Funding Source: | NIH/NCI |
| Role: | Recipient |
| Title: | ASCO Young Investigator Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | A Phase II Trial of mTOR Inhibitor Everolimus (RAD001) in Malignant Pleural Mesothelioma (MPM) |
| Funding Source: | Southwest Oncology Group |
| Role: | Principal Investigator |
| Title: | A Phase II study of TAS-106 in patients with recurrent or metastatic head and neck cancer refractory to Platinum-based chemotherapy |
| Funding Source: | Taiho Pharma USA |
| Role: | Principal Investigator |
| Title: | A Phase III CT, randomized double-blind, placebo-controlled trial of oral Suberolyanilide Hydroxamic acid (L-001078038) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy |
| Funding Source: | Merck and Company |
| Role: | Principal Investigator |
| Title: | Phase I CT trial of Imatinib Mesylate, Cisplatin, and Pemetrexed in unresectable malignant mesothelioma |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | A phase I/II trial of cisplatin, pemetrexed, cediranib in patients with unresectable malignant pleural mesothelioma |
| Funding Source: | Southwest Oncology Group |
| Role: | Principal Investigator |
| Title: | Individualized Combined Modality Therapy for Stage III Non-Small Lung Cancer (NSCLC) |
| Funding Source: | Radiation Therapy Oncology Group |
| Role: | Co-Principal Investigator |
| Title: | Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after completion of |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator-MDACC |
| Title: | Mesothelioma Global Tissue Project |
| Funding Source: | Hope Foundation |
| Role: | Principal Investigator |
| Title: | Phase II Randomized double-blind study comparing Tremelimumab to placebo in second or third line treatment of unresectable Pleural or peritoneal malignant Mesothelioma |
| Funding Source: | Medimmune LLC |
| Role: | Principal Investigator |
| Title: | TCGA Thymic Malignancies Project |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Dyadic yoga Program for Patients with Lung Cancer Undergoing Radiotherapy and their Family Caregivers |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Evaluation of the CDK4/6 inhibitor, LY2835219, in a preclinical model of mesothelioma |
| Funding Source: | Eli Lilly and Company |
| Role: | Principal Investigator |
| Title: | 2014-0497 A phase II trial of alisertib in salvage malignant mesothelioma |
| Funding Source: | Millennium |
| Role: | Principal Investigator |
| Title: | 2014-0722 DETERRED: PD-L1 blockadE To Evaluate the safety of Lung CanceR therapy using Carboplatin, Paclitaxel, and Radiation combinEd with MPDL3280A |
| Funding Source: | Genentech |
| Role: | Co-Principal Investigator |
| Title: | A Qualitative Interview Study to Assess the Content Validity of the Lung Cancer Symptom Scale - Mesothelioma (LCSS-Meso) |
| Funding Source: | Medimmune |
| Role: | Principal Investigator |
| Title: | Phase II study of Imatinib Mesylate and Docetaxel in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | AZD2171 in malignant pleural mesothelioma |
| Funding Source: | SWOG |
| Role: | Principal Investigator |
| Title: | Phase II study of imatinib mesylate and docetaxel in pretreated patients with metastatic NSCLC |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Phase I Trial of Adjuvant MK-3475 After Induction Chemotherapy and Hemithoracic Radiation Therapy for Unrecetable Malignant Pleural Mesothelioma |
| Funding Source: | Merck |
| Role: | Co-Principal Investigator |
| Title: | Double Blind, Randomized, Multicentre, Phase II Study of Nintedanib in Combination with Pemetrexed /Cisplatin Followed by Continuing Nintedanib Monotherapy versus Placebo in Combination with Pemetrexed/ Cisplatin followed by Continuing Placebo Monotherapy for the Treatment of Patients with Unresectable Malignant Pleural Mesothelioma |
| Funding Source: | Boehringer-Ingelheim Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Caboplatin as First Line Therapy in unresectable Pleural Mesothelioma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator |
| Title: | Phase II Trial of Adcetris (brentuximab vedotin) in CD30+ Malignant Mesothelioma |
| Funding Source: | Seattle Genetics |
| Role: | Principal Investigator |
| Title: | Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma |
| Funding Source: | Merck |
| Role: | Principal Investigator |
| Title: | SIV Division of Cancer Medicine Genentech SIV Alliance |
| Funding Source: | Genentech |
| Role: | Co-Principal Investigator |
| Title: | A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer |
| Funding Source: | ARIAD Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma |
| Funding Source: | Southwestern Oncology Group (SWOG) |
| Role: | Principal Investigator |
| Title: | Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Patients |
| Funding Source: | Southwestern Oncology Group (SWOG) |
| Role: | Principal Investigator |
| Title: | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1 PI |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression |
| Funding Source: | Polaris Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | A pilot to replace chemotherapy with ipilmumab-nivolumab in local -regionally advanced non-small cell lung cancer ( NSCLC) |
| Funding Source: | Bristol Myers Squibb Investigator Initiated Program |
| Role: | Principal Investigator |
| Title: | A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III NSCLC |
| Funding Source: | EMD Serono, Inc |
| Role: | Principal Investigator |
| Title: | A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced NSCLC (U01-01 Master) |
| Funding Source: | Merck |
| Role: | Principal Investigator |
| Title: | A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer |
| Funding Source: | AbbVie |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified March 06, 2024